Homepage4559 ⢠TYO
add
Zeria Pharmaceutical Co Ltd
Vorige slotkoers
„ 2.056,00
Dag-range
„ 2.044,00 - „ 2.060,00
Jaar-range
„ 1.970,00 - „ 2.505,00
Beurswaarde
108,68Ā mld. JPY
Gem. volume
79,13K
Koers/winst
9,08
Dividendrendement
2,30%
Primaire beurs
TYO
Marktnieuws
Financiƫle informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 22,54Ā mld. | 26,58% |
Bedrijfskosten | 14,54Ā mld. | 16,29% |
Netto inkomsten | 1,71Ā mld. | 347,11% |
Netto winstmarge | 7,59 | 295,12% |
Winst per aandeel | ā | ā |
EBITDA | 3,84Ā mld. | 90,15% |
Effectief belastingtarief | 18,34% | ā |
Balans
Totale activa
Totale passiva
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 23,59Ā mld. | 16,09% |
Totale activa | 159,17Ā mld. | 5,74% |
Totale passiva | 69,38Ā mld. | -1,88% |
Totaal aandelenvermogen | 89,80Ā mld. | ā |
Uitstaande aandelen | 44,08Ā mln. | ā |
Koers-boekwaardeverhouding | 1,01 | ā |
Rendement op activa | 3,09% | ā |
Rendement op kapitaal | 3,75% | ā |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 1,71Ā mld. | 347,11% |
Operationele kasstroom | ā | ā |
Kasstroom uit beleggingen | ā | ā |
Kasstroom uit financiering | ā | ā |
Nettomutatie in liquide middelen | ā | ā |
Vrije kasstroom | ā | ā |
Over
Zeria Shinyaku KÅgyÅ KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria YakushÅ Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
CEO
Opgericht
22 dec 1955
Website
Werknemers
1.777